WO2004108203A1 - 経皮投薬用パッドベース、及び注射針 - Google Patents
経皮投薬用パッドベース、及び注射針 Download PDFInfo
- Publication number
- WO2004108203A1 WO2004108203A1 PCT/JP2004/008513 JP2004008513W WO2004108203A1 WO 2004108203 A1 WO2004108203 A1 WO 2004108203A1 JP 2004008513 W JP2004008513 W JP 2004008513W WO 2004108203 A1 WO2004108203 A1 WO 2004108203A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- needle
- drug
- skin
- pad base
- biodegradable resin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/003—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0038—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a channel at the side surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
Definitions
- the present invention relates to a percutaneous administration pad base used for transdermally administering a drug acting on a living body into a living body, and a needle.
- the pad base is a portion for transdermally administering a drug in a transdermal administration pad.
- a transdermal administration pad is a pad base covered with, for example, an adhesive sheet from the side opposite to the skin. For example, when using the pad base surface to stick to the skin.
- the skin acts as a barrier that protects the body, preventing foreign substances from entering the body.
- the outer stratum corneum which is in direct contact with foreign matter, plays a large role as a barrier.
- the gastrointestinal tract is the same in that it comes into direct contact with foreign substances outside the body, the gastrointestinal tract does not have a barrier such as the stratum corneum like the skin, but rather actively excretes foreign substances, that is, nutrients from food. They are composed of nutrient-absorbing cells that have the function of taking up cells, and in this regard, they differ greatly.
- the skin also has the function of excreting it out of the living body (the insensitive evaporative function).
- the skin is not a simple protective film but an organ that has a function of regulating the penetration of substances. .
- transdermal absorption type '' Pharmaceuticals such as nitroglycerin, isosorbide dinitrate, estradiol, llobuterol, nicotine, clonidine, scopolamine, phenynil, and lidocaine have been developed.
- MicroPatch which uses a pad with a myriad of small needles on the skin and injects the drug from the puncture site, as a means of making micro perforations in the skin, similar to electroporation. was suggested.
- the transdermal administration pad used in this micropatch method is a pyramid-shaped, 10 to 50 m thick and short solid needle (made of silicon, metal, or plastic). It is equipped with a plurality of tubes and a reservoir that is a chemical solution tank. In use, the needle is pierced into the skin, and the contact surface between the needle and the skin is shaken with a vibration device (100 MHz to 2000 MHz) to create a gap. The drug solution from the reservoir is allowed to penetrate into the skin from the micro-perforated portion of the skin (see, for example, US Pat. No. 6,183,434).
- Insulin, morphine, para-interferon, parathyroid hormone, erythropoietin, etc. have been developed as drugs to be administered by the micropatch method (Altea Therapeutics, Atlanta, USA). Now in phase one, research for practical application is underway. Other methods of administration include needle-free injection, which is in contrast to the above method.Specifically, injection is performed under a high pressure on the injection solution, or the drug powder is injected under high pressure. A method using high-pressure gas that is injected under the skin by applying gas has been proposed, and some of them have already been commercialized.
- the micropatch method is an excellent method from the viewpoint that it does not require a dedicated device and can be easily used by anyone. Disclosure of the invention
- the reason that the conventional micropatch method uses a thin and short needle as described above is that if the needle is long and thin, it easily breaks and remains in the skin, which may adversely affect the living body. .
- the drug must be administered by vibration as described above.Therefore, the permeation of the drug through the skin is affected by the presence or absence of the vibration, and the drug is administered when administered. A power supply is required.
- a thin needle is required to relieve pain with a normal injection needle, but if it is too thin, there is a concern that it may break. If it breaks, it may remain in the skin and adversely affect the living body.
- the present invention has been made in view of the above circumstances, and a purpose thereof is to provide a transdermal administration pad that has almost no adverse effect on a living body even when a needle is broken and remains in the skin in a micropatching method.
- a base To provide a base.
- a pad base for percutaneous administration is a pad base for percutaneous administration in which fine needles are erected on the skin side of a substrate to be attached to the skin, wherein at least the fine needles are formed of a biodegradable resin.
- the hollow shaft core is configured to be filled with a drug to be administered, or a biodegradable resin and a drug to be administered are mixed to form a hollow or solid shape.
- the drug to be administered to the hollow shaft center of the fine needle It may be one filled with an agent. Also, it may be used as a tube for feeding the administered drug. Note that the number of the fine needles standing from the attachment base material is not limited to one, but may be plural.
- One of the embodiments of the fine needle in the pad base for transdermal administration is a tubular material made of a biodegradable resin having an open end, which can be filled with a drug in the tube.
- a microneedle pierces the skin by attaching a transdermal drug administration pad to the skin, and the drug in the microneedle is administered into the skin.
- the fine needle is made of a biodegradable resin, so that it is decomposed in a living body and has almost no adverse effect on the living body.
- the tubular microneedle may be composed of a biodegradable resin and a drug to be administered. In this case, the drug is also administered by dissolving (decomposing) the fine needle itself in a living body.
- the both ends may be closed and the drug may be enclosed in a tube, and the encapsulated drug is released by decomposing the fine needle in a living body. It becomes.
- the fine needle is not only composed of a biodegradable resin, but may be composed of a biodegradable resin and a drug to be administered.
- a solid needle-like material may be used. You may make it do.
- the form of drug contained in the fine needle is as follows: the drug is encapsulated, the drug is filled in a cylindrical shape with one open end, and the drug is kneaded into the biodegradable resin of the fine needle itself.
- the administration conditions of the drug such as immediate action and sustained release, can be changed by various selections.
- the pad for transdermal administration using the pad base of the present invention as described above, it is possible to perform transdermal absorption simply by sticking it to the skin without depending on the administration technique by vibration. Therefore, a power supply for vibration and the like are not required, which is more simple.
- the biodegradable resin include polylactic acid, polyethylene succinate, polybutylene succinate adipate, polybutylene succinate carbonate, polycaprolactone, polyesteramide, polyester polyester, polypinyl alcohol, and polyhydroxyl.
- Petrilate, mantriose, cellulose, cellulose acetate, collagen, and a mixture of two or more selected from these are recommended, and polylactic acid or a copolymer of lactic acid and glycolic acid is particularly preferable.
- a lactic acid / glycolic acid copolymer is already used as a pharmaceutical, and is hydrolyzed into lactic acid in tissues to gradually disappear.
- the drug for administration may be any of liquid, cream, gel, suspension, and powder, and is substantially limited except for drugs that are not suitable for transdermal administration. is not.
- the drug is kneaded into a biodegradable resin raw material, and the mixture is cured.
- the drug to be mixed with the biodegradable resin is not necessarily the same as the drug to be filled in the hollow portion.
- the drug to be mixed with the biodegradable resin while exhibiting the same drug effect as the drug in the hollow portion is used.
- a drug that is easy may be used.
- the needle after piercing the skin, the needle may be actively broken and left in the skin. When implanted in the skin in this way, the transdermal administration pad body does not peel off and the administration is not interrupted, so that the drug can be released continuously for a long period of time.
- the fine needle preferably has an outer diameter of 20 or more and 500 or less, an inner diameter of 10; m or more and 490 or less, and a length of 100 or more zm and 1 mm or less. .
- the fine needle and the attaching base may be integrally formed of the same material.
- the attaching base is also biodegradable. Made of resin or biodegradable resin and drug for administration With little adverse effect.
- the injection needle according to the present invention is characterized in that at least the needle portion of the injection needle is made of a biodegradable resin, or is made of a mixture of a biodegradable resin and a drug to be administered. I do.
- the needle portion of the injection needle is made of a biodegradable resin or a mixture of the biodegradable resin and the administered drug, so that the needle portion can be separated in vivo. It is understood that it has almost no adverse effect on the living body.
- biodegradable resin used for the injection needle the same one as described above can be used.
- polylactic acid or a copolymer of lactic acid and glycolic acid is preferable.
- FIG. 1 is a cross-sectional view for explaining the shape of the hollow portion of the fine needle in the pad base for transdermal administration according to the present invention.
- FIG. 2 is a view showing a pad base for transdermal administration according to an embodiment of the present invention.
- Figure 3 (a) is a micrograph of the microneedle on the transdermal dosing pad base of Example 10, and (b) is a schematic diagram thereof.
- the percutaneous administration pad base and the injection needle according to the present invention will be specifically described with reference to the drawings showing examples.
- the present invention is not necessarily limited to the illustrated examples. It is also possible to implement the present invention with appropriate modifications within a range that can be adapted to the gist of the present invention, and all of them are included in the technical scope of the present invention.
- FIGS. 2A and 2B are views showing a transdermal administration pad base according to an embodiment of the present invention, wherein FIG. 2A is a cross-sectional view and FIG. 2B is a top view.
- the upper side in Fig. 2 (a) is the surface to be attached to the skin.
- Examples of the transdermal administration pad include a pad in which an adhesive sheet is covered from the side opposite to the skin (the lower side in FIG. 2 (a)) of the pad base. It is used by sticking it to the skin by the adhesive force. Alternatively, the drug may be given by piercing the needle by holding it against the skin without an adhesive.
- both the fine needle 1 and the sticking substrate 2 are made of a biodegradable resin (for example, polylactic acid). It is preferable to manufacture the fine needle 1 and the bonding substrate 2 by integral molding.
- the hollow portion 3 of the fine needle 1 is filled in such a manner that a chemical solution is sucked from a chemical solution container.
- the microneedle 1 is punctured into the living body by applying a pressure on the base material 2 to be applied to the skin by applying a transdermal drug administration pad to the skin, and the drug solution in the hollow portion 3 from the tip of the microneedle 1. Is injected into a living body.
- the shape of the fine needle 1 is such that the outer wall of the fine needle 1 is widened toward the base 2 toward the attachment base material 2.
- the shape is not limited to this, and the outer wall is straight. It may be.
- the depth of the hollow portion 3 of the fine needle 1 may be deeper than that shown in FIG.
- the depth L of the hollow portion 3 is smaller than the height H of the fine needle 1 as shown in FIG. 1 (a) [H> L (semi-hollow type: TY PE 1 )].
- H> L sin-hollow type: TY PE 1
- the curvature is infinite here, that is, a flat shape.
- the portion below this plane with the portion as the boundary surface is referred to as the attachment substrate 2, and the portion standing therefrom is referred to as the fine needle 1.
- each microneedle 1 in a pad base having a plurality of microneedles 1 may all be the same as shown in FIG. 2, or may be combined at different depths.
- TYPE 4 FIG. 1 (d)
- the medicine may be supplied from here to continuously administer the medicine.
- microneedle such that the microneedle is positively folded after piercing the skin with the microneedle. Furthermore, when this transdermal administration pad base is used, administration can be performed without vibration as in the conventional micropatch method, and therefore, administration is not required, so that administration can be performed more easily. . .
- the needle part is made of a biodegradable resin (for example, polylactic acid).
- the shape of the needle part is the same as that of a normal injection needle, and a thinner needle is recommended from the viewpoint of pain relief.
- a stainless steel wire with a length of about 30 mm and a thickness of ⁇ 280 ⁇ ⁇ is formed in a grid on a rubber plate with 5 wires vertically and 6 wires at intervals of 2 mm as a mold material for forming fine needles.
- the above polylactic acid The concentrations of polylactic acid in the loroform solution were adjusted to 5, 6, and 7 wt%, and the pad bases obtained for each were designated as Examples 1, 2, and 3, respectively.
- Each of Examples 1 to 3 above was a pad base for transdermal administration having a plurality of fine needles having a shape as shown in FIG. 1 (d).
- the tip of the stainless steel wire of this mold was vertically contacted with the bottom of a stainless steel dish.
- 3 ml of a formaldehyde solution of polylactic acid having a molecular weight of 67,400 was injected, and the polylactic acid was solidified by standing and air-drying. Thereafter, the stainless steel wire was pulled out and taken out of the stainless steel dish to obtain a transdermal administration pad base.
- the polylactic acid having a concentration of 10, 11, and 12 wt% as the concentration of the polylactic acid in the solution of polylactic acid in the mouth of the mouth was adjusted, and the pad bases obtained for the respective solutions were used as Examples 4, 5, and 6. -.
- the pad base for transdermal administration had a plurality of fine needles having a shape as shown in FIG. 1 (d).
- the tip of the stainless steel wire of this mold was vertically contacted with the bottom of a stainless steel dish.
- 3 ml of a solution of polylactic acid having a molecular weight of 258 and 700 in the form of black mouth was poured into the stainless steel dish, and allowed to stand and air-dried to solidify the polylactic acid. Thereafter, the stainless steel wire was pulled out and taken out of the stainless steel dish to obtain a transdermal administration pad base.
- the polylactic acid concentrations of 1, 2, and 3 wt% in the above-mentioned solution of polylactic acid were adjusted to 1, 2, and 3 wt%, and the bad bases obtained for each were designated as Examples 7, 8, and 9, respectively.
- Each of the above Examples 7 to 9 was a pad base for transdermal administration having a plurality of fine needles having a shape as shown in FIG. 1 (d).
- the tip of the stainless steel wire of this mold is set up perpendicular to the bottom while leaving a little space from the bottom of the stainless steel dish. It was arranged like.
- polylactic acid high molecular weight PLA
- 0.1 part by weight of the polylactic acid having a molecular weight of 10,000 low molecular weight PLA
- the polylactic acid was poured into a stainless steel dish so that one end of the stainless steel wire was immersed, and allowed to stand and air-dried to solidify the polylactic acid.
- transdermal administration pad base The polylactic acid concentrations of 5, 6, and 7 wt% in the high-molecular-weight PLA black-mouthed form solution were adjusted, and the pad bases obtained for each were designated as Examples 10, 11, and 12, respectively.
- FIG. 3 (a) shows a microphotograph (magnification: 40) of the fine needle obtained in Example 10.
- Fig. 3 (b) shows a schematic diagram.
- Each of the above Examples 13 to 15 was a pad base for transdermal administration having a plurality of fine needles having a shape as shown in FIG.
- Examples 16-18> The same fine needle mold as in Examples 1 to 3 above was used, and the tip of the stainless steel wire of this mold was arranged so as to be perpendicular to the bottom of the stainless steel dish with a gap.
- polylactic acid high molecular weight PLA
- a solution of polylactic acid (high molecular weight PLA) having a molecular weight of 258,700 (a high molecular weight PLA) in the mouth of a mouth 0.1 part by weight of the polylactic acid (a low molecular weight PLA) having a molecular weight of 10,000 is added. Then, 3 ml of this mixed solution was poured into the stainless steel dish, and one end of the stainless steel wire was immersed. The solution was pushed up on the stainless steel wire, allowed to stand, and air-dried.
- the lactic acid was solidified. Thereafter, the stainless steel wire was pulled out and taken out of the stainless steel dish to obtain a transdermal administration pad base.
- the polylactic acid concentration in the chloroform solution of high molecular weight PLA was adjusted to 1, 2, and 3 wt%, and the pad bases obtained for the respective samples were used as examples 16, 17, and 18.
- Each of Examples 16 to 18 above was a pad base for transdermal administration having a plurality of fine needles having a shape as shown in FIG. 1 (c).
- Tables 1 to 9 show the above examples and Tables 10 to 18 show the above examples.
- pad bases in Examples 1 to 18 above are all made of polylactic acid, even if the fine needles are broken and remain in the skin during use, they will be biodegraded. is expected.
- examples 1 to 3, and 10 to 12 are more preferable among the above examples.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/560,096 US20060127465A1 (en) | 2003-06-10 | 2004-06-10 | Pad base for transdermal administration and needle |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003165250 | 2003-06-10 | ||
JP2003-165250 | 2003-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004108203A1 true WO2004108203A1 (ja) | 2004-12-16 |
Family
ID=33508846
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/008513 WO2004108203A1 (ja) | 2003-06-10 | 2004-06-10 | 経皮投薬用パッドベース、及び注射針 |
PCT/JP2004/008514 WO2004108204A1 (ja) | 2003-06-10 | 2004-06-10 | 経皮投薬用パッドベースの製造方法及び経皮投薬用パッドベース、並びに注射針 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/008514 WO2004108204A1 (ja) | 2003-06-10 | 2004-06-10 | 経皮投薬用パッドベースの製造方法及び経皮投薬用パッドベース、並びに注射針 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20060127465A1 (ja) |
EP (1) | EP1632263A4 (ja) |
AU (1) | AU2004244909A1 (ja) |
CA (1) | CA2528512A1 (ja) |
WO (2) | WO2004108203A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006018642A1 (en) * | 2004-08-16 | 2006-02-23 | Functional Microstructures Limited | Method of producing a microneedle or microimplant |
WO2006101459A1 (en) * | 2005-03-23 | 2006-09-28 | Agency For Science, Technology And Research | Microneedles |
JP2015186581A (ja) * | 2004-12-28 | 2015-10-29 | ナブテスコ株式会社 | 皮膚用針製造装置および皮膚用針製造方法 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006345983A (ja) * | 2005-06-14 | 2006-12-28 | Nabtesco Corp | 皮膚用針集合体 |
JPWO2008020633A1 (ja) * | 2006-08-18 | 2010-01-07 | 凸版印刷株式会社 | マイクロニードル及びマイクロニードルパッチ |
JP2008284318A (ja) * | 2007-05-15 | 2008-11-27 | Kosumedei Seiyaku Kk | 生体由来物質からなる投薬用微細針 |
WO2009021048A2 (en) | 2007-08-06 | 2009-02-12 | Transderm, Inc. | Microneedle arrays formed from polymer films |
CN102076357A (zh) * | 2008-06-30 | 2011-05-25 | 久光制药株式会社 | 微针装置以及利用微针装置提高流感疫苗的功效性的方法 |
CA2734778C (en) | 2008-08-21 | 2017-06-06 | Third Rock Ventures | Device for drug evaluation and local treatment |
WO2010059605A2 (en) * | 2008-11-18 | 2010-05-27 | 3M Innovative Properties Company | Hollow microneedle array and method |
WO2010143689A1 (ja) * | 2009-06-10 | 2010-12-16 | 久光製薬株式会社 | マイクロニードルデバイス |
EP2457592B1 (en) * | 2009-07-23 | 2020-09-16 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle array |
KR101152486B1 (ko) | 2009-07-31 | 2012-06-01 | (주)테라젝코리아 | 마이크로니들 패드 제조방법 및 이를 위한 제조장치 |
WO2011156641A2 (en) * | 2010-06-09 | 2011-12-15 | Kaspar Roger L | Microneedle arrays for active agent delivery |
US20130184593A1 (en) | 2011-12-30 | 2013-07-18 | Kibur Medical, Inc. | Implantable Devices And Methods For The Evaluation of Active Agents |
US20150005595A1 (en) | 2011-12-30 | 2015-01-01 | Kibur Medical, Inc. | Implantable devices and methods for evaluation of active agents |
WO2014073531A1 (ja) | 2012-11-09 | 2014-05-15 | 凸版印刷株式会社 | 針状構造体及びその製造方法 |
US20160279401A1 (en) | 2015-03-27 | 2016-09-29 | Allergan, Inc. | Dissolvable microneedles for skin treatment |
JP6565906B2 (ja) | 2014-05-20 | 2019-08-28 | 凸版印刷株式会社 | 針状体の製造方法、及び針状体 |
JPWO2016072060A1 (ja) | 2014-11-05 | 2017-09-14 | 凸版印刷株式会社 | マイクロニードルセット |
WO2016072350A1 (ja) | 2014-11-07 | 2016-05-12 | 凸版印刷株式会社 | 経皮投薬用針集成体及びその製造方法 |
CN107206220A (zh) | 2015-02-16 | 2017-09-26 | 凸版印刷株式会社 | 微针 |
JP2020507422A (ja) | 2017-02-17 | 2020-03-12 | アラーガン、インコーポレイテッドAllergan,Incorporated | 活性成分を含むマイクロニードルアレイ |
KR102188397B1 (ko) * | 2018-07-04 | 2020-12-08 | 주식회사 지엘캄퍼니 | 마이크로 니들 |
CN110279935B (zh) * | 2019-07-11 | 2022-01-07 | 上海揽微医学科技有限公司 | 棱形硅微针及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999033504A1 (en) * | 1997-12-31 | 1999-07-08 | Minimed Inc. | Insertion device for an insertion set and method of using the same |
WO2002007813A1 (en) * | 2000-07-21 | 2002-01-31 | Smithkline Beecham Biologicals S.A. | Vaccines |
JP2002517300A (ja) * | 1998-06-10 | 2002-06-18 | ジョージア テック リサーチ コーポレイション | 微小針デバイスおよび製造方法ならびにそれらの使用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5392588A (en) | 1977-01-22 | 1978-08-14 | Shiyuuichi Sakai | Syringe needle |
US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
US6379324B1 (en) | 1999-06-09 | 2002-04-30 | The Procter & Gamble Company | Intracutaneous microneedle array apparatus |
US6623457B1 (en) * | 1999-09-22 | 2003-09-23 | Becton, Dickinson And Company | Method and apparatus for the transdermal administration of a substance |
US6511463B1 (en) * | 1999-11-18 | 2003-01-28 | Jds Uniphase Corporation | Methods of fabricating microneedle arrays using sacrificial molds |
US6565532B1 (en) * | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
WO2001091846A2 (en) * | 2000-05-26 | 2001-12-06 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
FR2809625B1 (fr) | 2000-06-05 | 2002-08-09 | Ussel Bernard D | Nouvelle aiguille pour dispositif medical et dispositif en comportant |
WO2002064193A2 (en) * | 2000-12-14 | 2002-08-22 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
WO2002074173A1 (en) * | 2001-03-16 | 2002-09-26 | Alza Corporation | Method and apparatus for coating skin piercing microprojections |
US6767341B2 (en) | 2001-06-13 | 2004-07-27 | Abbott Laboratories | Microneedles for minimally invasive drug delivery |
US6686299B2 (en) * | 2001-06-21 | 2004-02-03 | Carlo D. Montemagno | Nanosyringe array and method |
WO2003026733A2 (en) | 2001-09-28 | 2003-04-03 | Biovalve Technologies, Inc. | Microneedle with membrane |
-
2004
- 2004-06-10 US US10/560,096 patent/US20060127465A1/en not_active Abandoned
- 2004-06-10 WO PCT/JP2004/008513 patent/WO2004108203A1/ja active Application Filing
- 2004-06-10 AU AU2004244909A patent/AU2004244909A1/en not_active Abandoned
- 2004-06-10 WO PCT/JP2004/008514 patent/WO2004108204A1/ja active Application Filing
- 2004-06-10 CA CA002528512A patent/CA2528512A1/en not_active Abandoned
- 2004-06-10 EP EP04736595A patent/EP1632263A4/en not_active Withdrawn
- 2004-06-10 US US10/560,085 patent/US7347835B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999033504A1 (en) * | 1997-12-31 | 1999-07-08 | Minimed Inc. | Insertion device for an insertion set and method of using the same |
JP2002517300A (ja) * | 1998-06-10 | 2002-06-18 | ジョージア テック リサーチ コーポレイション | 微小針デバイスおよび製造方法ならびにそれらの使用 |
WO2002007813A1 (en) * | 2000-07-21 | 2002-01-31 | Smithkline Beecham Biologicals S.A. | Vaccines |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006018642A1 (en) * | 2004-08-16 | 2006-02-23 | Functional Microstructures Limited | Method of producing a microneedle or microimplant |
EP2272430A1 (en) * | 2004-08-16 | 2011-01-12 | Functional Microstructures Limited | Method of producing a microneedle or microimplant |
US8192787B2 (en) | 2004-08-16 | 2012-06-05 | Innoture Limited | Method of producing a microneedle or microimplant |
JP2015186581A (ja) * | 2004-12-28 | 2015-10-29 | ナブテスコ株式会社 | 皮膚用針製造装置および皮膚用針製造方法 |
JP2019013826A (ja) * | 2004-12-28 | 2019-01-31 | ナブテスコ株式会社 | 針集合体 |
WO2006101459A1 (en) * | 2005-03-23 | 2006-09-28 | Agency For Science, Technology And Research | Microneedles |
Also Published As
Publication number | Publication date |
---|---|
EP1632263A1 (en) | 2006-03-08 |
US20060163215A1 (en) | 2006-07-27 |
US7347835B2 (en) | 2008-03-25 |
WO2004108204A1 (ja) | 2004-12-16 |
CA2528512A1 (en) | 2004-12-16 |
AU2004244909A1 (en) | 2004-12-16 |
US20060127465A1 (en) | 2006-06-15 |
EP1632263A4 (en) | 2008-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004108203A1 (ja) | 経皮投薬用パッドベース、及び注射針 | |
JP2005021677A (ja) | 経皮投薬用パッドベース、及び注射針 | |
JP5267910B2 (ja) | マイクロニードルアレイ | |
JP5063544B2 (ja) | 経皮吸収シート及びその製造方法 | |
Chen et al. | Preparation, properties and challenges of the microneedles-based insulin delivery system | |
JP4427691B2 (ja) | マイクロニードルアレイ | |
US8419708B2 (en) | Transdermal drug administration apparatus having microneedles | |
WO2008020632A1 (fr) | Micro-aiguille et timbre à micro-aiguilles | |
CN102000020B (zh) | 新型可降解聚合物微针贴剂及其制备方法 | |
JP5472673B2 (ja) | マイクロニードルアレイ | |
JP2005021678A (ja) | 経皮投薬用パッドベースの製造方法及び経皮投薬用パッドベース、並びに注射針 | |
CN104117137A (zh) | 一种胶囊式中空载药微针阵列及其制备方法 | |
JP2010233673A (ja) | 経皮吸収シート及びその製造方法 | |
WO2002015801A1 (en) | Substance delivery system | |
WO2004060473A2 (en) | Active agent delivery device having composite members | |
Bala et al. | Transdermal drug delivery system (TDDS)-a multifaceted approach for drug delivery | |
JP5063543B2 (ja) | 経皮吸収シートの製造方法 | |
KR101724654B1 (ko) | 마이크로 니들 패치 및 그의 제조 방법 | |
JP2009254756A (ja) | マイクロニードルアレイ | |
PT1684846E (pt) | Dispositivo para a administração transdérmica de substâncias activas | |
CN105031744A (zh) | 一种增生性瘢痕用微针及其制备方法 | |
JP6003338B2 (ja) | 針状体パッケージ | |
CN210494885U (zh) | 金属储药微针贴片 | |
JP6255759B2 (ja) | マイクロニードル | |
CN217014772U (zh) | 气泡式空心微针 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006127465 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10560096 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10560096 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |